• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors for Motor Recovery in Non-depressed Patients After Acute Stroke: A Meta-Analysis
Conclusions: Fluoxetine and citalopram can promote motor recovery in non-depressed patients with acute stroke, but it is necessary to pay attention to the possible AEs of fluoxetine, such as hyponatremia, seizure and fracture.Systematic Review Registration: PROSPERO, identifier [CRD42021227452].
Source: Frontiers in Neurology - October 20, 2021 Category: Neurology Source Type: research

Prestroke Physical Activity and Poststroke Cognitive Performance
Conclusion: Higher prestroke PA was associated with a better cognitive performance as measured by the SDMT at 1 and 6 months poststroke. We found no significant association between prestroke PA and functional outcome. Our results are encouraging and support further investigations of PA as a protective measure against poststroke cognitive impairment.Cerebrovasc Dis
Source: Cerebrovascular Diseases - November 11, 2020 Category: Neurology Source Type: research

Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation
Conclusion: There was no difference in cognition between citalopram and placebo-treated patients according to the genotype group. Our results indicate, however, that low expression SERT genotype may contribute to reduced cognitive function post stroke as placebo-treated patients with low SERT expression tended to score lower on the SDMT. The significant difference in SDMT scores between low and high expression patients was present only in the placebo-treated group, thereby warranting further exploration of the potential effect of early citalopram treatment on cognitive functioning. Our results are preliminary and need repl...
Source: Cerebrovascular Diseases - March 7, 2019 Category: Neurology Source Type: research

Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta ­Analysis
To objectively evaluate the efficacy and safety of citalopram versus other antidepressant drugs in poststroke depression (PSD) treatment.
Source: Journal of Stroke and Cerebrovascular Diseases - September 7, 2018 Category: Neurology Authors: Min Cui, Chao Yun Huang, Fang Wang Tags: Review Article Source Type: research

Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis
Background and Purpose: To evaluate the citalopram in post-stroke depression treatment, we compared its use to other selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and traditional Chinese medicines (TCMs). Methods: We searched databases up to May 2015. Relative risk (RR) for dichotomous data and standard mean difference (SMD) for continuous variables were analyzed using Stata 13.1. Results: The RR of the efficacy index compared to TCAs was 1.07 (95% CI 1.01-1.14, p = 0.02), and the Hamilton Depression Scale with citalopram was lower than that found with other SSRIs (SMD -0.43, 95% CI -0.85 to -0.01, p
Source: European Neurology - November 11, 2015 Category: Neurology Source Type: research

TALOS: a multicenter, randomized, double‐blind, placebo‐controlled trial to test the effects of citalopram in patients with acute stroke
DiscussionSSRI treatment is well tolerated and overall beneficial in the wake of stroke; it may also be neuroprotective and prevent new vascular events.
Source: International Journal of Stroke - April 8, 2015 Category: Neurology Authors: Kristian Lundsgaard Kraglund, Janne Kaergaard Mortensen, Erik Lerkevang Grove, Søren Paaske Johnsen, Grethe Andersen Tags: Protocol Source Type: research

A Case Report of Acute Intracerebral Vascular Ischemic Stroke After Treatment with Dihydroergotamine in a * Patient with New Onset of Migraine New Daily Persistant Headache with Thunderclap Onset (S41.008)
CONCLUSIONS: We report this case of a Stroke occuring in a patient who failed conventional outpatient management of sudden onset migraine-like headache that we suspect may have been on the spectrum of RCVS. Prior to this no reports have been published on a stroke possibly being a side effect or complication of DHE therapy. One prior report has suggested DHE caused RCVS in a migraine patient on citalopram, supporting the concept that DHE should be avoided in the setting of recent onset RCVS.Disclosure: Dr. Ghafoor has nothing to disclose. Dr. Young has received personal compensation for activities with Merck & Co. Inc. ...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ghafoor, S., Young, W. Tags: Headache: Clinical Source Type: research

A Case Report of Dihydroergotamine Administration for Status Migrainosus in a Patient on Longstanding Citalopram Causing a Fatal Reversible Cerebral Vasoconstriction Syndrome (RCVS) (P02.027)
CONCLUSIONS: We report this case report of fatal RCVS of a patient on long standing citalopram who developed this after being administered Dihydroergotamine for status migrainosus. As this is thought to be a self-limiting in terms of clinical features. However, some patients may have more severe focal neurologic symptoms and signs, including ischemic or hemorrhagic strokes as described in our patient.Disclosure: Dr. Asi has nothing to disclose. Dr. Gomes has nothing to disclose. Dr. Dani has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Asi, K., Gomes, J., Dani, D. Tags: P02 Cerebrovascular Disease II Source Type: research